Platinum-based doublet chemotherapy prolongs survival and improves quality of life as first-line treatment for non-selected and good performance status patients with advanced nonsmall cell lung cancer (NSCLC) [1]. However, the survival benefit is limited, even if this combination is the standard of care for decades, no clinically relevant predictive biomarkers have been discovered so far. The i...

As the most essential biological characteristic in malignant tumors, infiltration and metastasis are the leading cause for the deaths of patients with tumors. At present, the morbidity and mortality of lung cancer are the highest among malignant tumors all over the world, in which most of them result from infiltration and metastasis (Li et al., 2013; Fei et al., 2013; Huang et al., 2013; Cui et...

The up-regulation of fucosyltransferase 8 (FUT8), the only enzyme catalyzing α1,6-fucosylation in mammals, has been observed in several malignant cancers including liver, ovarian, thyroid, and colorectal cancers. However, the pathological role and the regulatory mechanism of FUT8 in cancers remain largely unknown. In the current study, we report that the expression of FUT8 is up-regulated in no...

Background: Lung cancer is a leading cause of cancer-related mortality worldwide. The purpose our meta-analysis was to assess the risk factors for brain metastases (BM) in patients with non-small cell lung (NSCLC).

OBJECTIVES To evaluate the diagnostic value of serum p16 gene promoter methylation for diagnosis of nonsmall cell lung cancer (NSCLC). MATERIALS AND METHODS By searching the databases of PubMed and CNKI, we included all the published articles related serum p16 gene promoter methylation and nonsmall lung cancer. The true positive, false positive, false negative, and true negative data for each...

In the context of the European Respiratory Society (ERS) plan for thoracic oncology [1], in 2014 the European Respiratory Journal (ERJ) initiated a series of reviews called “Challenges and controversies in thoracic oncology” [2]. The following questions were addressed. The specific contribution of each thoracic staging and treatment modality has not always been unequivocally established: which ...

Ferroptosis therapy gradually becomes a new strategy for the treatment of non-small cell lung cancer (NSCLC) because its active iron metabolism. Because hypoxic microenvironment in NSCLC inhibits ferroptosis heavily,...

Lung cancer is the leading cause of cancer-related mortality in both men and women and approximately 219,440 new cases of nonsmall cell lung cancer (NSCLC) were estimated to occur in the USA in 2009, which caused 159,390 NSCLC-related deaths. More than 50% of cases of advanced NSCLC are diagnosed in patients older than age 65, and recent Surveillance Epidemiology and End Results (SEERs) data su...

Separation of small cell lung carcinoma (SCLC) from nonsmall cell lung carcinoma (NSCLC) is a critical distinction to be made in the diagnosis of lung cancer. However, the diagnosis of SCLC is most commonly made on small biopsies and cytologic specimens, and practicing pathologists may not be familiar with all its morphologic guises and frequent combination with NSCLC elements, which may be see...

Previous studies suggested that diabetes mellitus (DM) was associated with risk and mortality of cancer, but studies investigating the correlation between DM and lung cancer prognosis remain controversial. Herein, a meta-analysis was performed to derive a more precise estimate of the prognostic role of DM in lung cancer.Medline and Embase were searched for eligible articles from inception to Oc...